Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNDX-62122
- Development stage
- Preclinical
- Lead developer
- Syndax Pharmaceuticals
- Modality
- Small Molecules
01
Overview
SNDX-62122 is an internally developed, next-generation small molecule menin inhibitor being developed by Syndax Pharmaceuticals for the treatment of myelofibrosis. It is designed to offer higher potency, improved selectivity, optimized pharmacokinetics, and a potentially more combinable profile compared to its parent molecule, revumenib. Preclinical data has identified menin as a novel dependency in atypical megakaryocytes and early megakaryocyte progenitors that drive myelofibrosis pathology. SNDX-62122 is wholly owned by Syndax and has activity against common resistance mutations. An IND submission and Phase 1 clinical trial are both targeted for 2027.
02
Targets
MEF2CMEIS1MEN1 (Menin)
Beyond the preview
Go deeper on SNDX-62122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNDX-62122.